Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eliprodil
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eliprodil is a small molecule, investigational drug that acts as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, with selectivity for the NR2B (GluN2B) subunit at submicromolar concentrations[3][5][6]. It also exhibits activity as a calcium channel blocker and has been described as neuroprotective[1][5]. Eliprodil was developed primarily for neurological indications such as acute ischemic stroke, traumatic brain injury, Parkinson's disease, and other movement disorders[1][2][3]. The drug failed to demonstrate efficacy in Phase III clinical trials for acute ischemic stroke and head injuries and its development was discontinued for these indications by Synthélabo Recherche (now part of Sanofi)[3][7].
- Other names
- (4-chlorophenyl)-4-((4-fluorophenyl)methyl)-1-piperidineethanol
02
Targets
ADRA1A (α1A)GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)CaV (Voltage-gated calcium channel protein complex)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on eliprodil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eliprodil.